Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Neoplasms|HRpos Breast Neoplasms|BRCA 1 /2 and / or HRD
Interventions: DRUG: PwO|DRUG: PwCb|DRUG: EC|PROCEDURE: Surgery after neoadjuvant Therapy|OTHER: Stratification
Sponsor: German Breast Group
Collaborators: AstraZeneca